Abstract
Hypoxia-inducible factor-1 (HIF-1), a heterodimeric (containing α and β subunits) transcription factor, is involved in hypoxia response pathway that regulates the expression of many tumorrelated genes. The stabilized HIF-1 heterodimer couples to the general co-activators p300/CBP (CREB binding protein), forming an active transcription factor to initiate hypoxic responses. Inhibiting the transcription factor-coactivator HIF-1α-p300/CBP interaction represents an attractive approach for blocking hypoxia pathway in tumors. Recently, diverse HIF-1α-p300/CBP inhibitors have been designed and their anti-tumor activities have been evaluated. The developments of inhibitors of HIF-1α- p300/CBP are discussed in this review. An outline of structures and biological activities of these inhibitors can be traced, along with the approaches for inhibitors discovery. The challenges in identifying novel and selective potent inhibitors of HIF-1α-p300/CBP are also put forward.
Keywords: Anticancer, cancer therapy, HIF-1α/p300 inhibitors, hypoxia response pathway, hypoxia-inducible factor-1, p300/CREB binding protein.
Mini-Reviews in Medicinal Chemistry
Title:Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents
Volume: 18 Issue: 4
Author(s): Jinlian Wei, Yingrui Yang, Mengchen Lu, Yonghua Lei, Lili Xu, Zhengyu Jiang, Xiaoli Xu, Xiaoke Guo, Xiaojin Zhang, Haopeng Sun*Qidong You
Affiliation:
- Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009,China
Keywords: Anticancer, cancer therapy, HIF-1α/p300 inhibitors, hypoxia response pathway, hypoxia-inducible factor-1, p300/CREB binding protein.
Abstract: Hypoxia-inducible factor-1 (HIF-1), a heterodimeric (containing α and β subunits) transcription factor, is involved in hypoxia response pathway that regulates the expression of many tumorrelated genes. The stabilized HIF-1 heterodimer couples to the general co-activators p300/CBP (CREB binding protein), forming an active transcription factor to initiate hypoxic responses. Inhibiting the transcription factor-coactivator HIF-1α-p300/CBP interaction represents an attractive approach for blocking hypoxia pathway in tumors. Recently, diverse HIF-1α-p300/CBP inhibitors have been designed and their anti-tumor activities have been evaluated. The developments of inhibitors of HIF-1α- p300/CBP are discussed in this review. An outline of structures and biological activities of these inhibitors can be traced, along with the approaches for inhibitors discovery. The challenges in identifying novel and selective potent inhibitors of HIF-1α-p300/CBP are also put forward.
Export Options
About this article
Cite this article as:
Wei Jinlian, Yang Yingrui, Lu Mengchen, Lei Yonghua, Xu Lili, Jiang Zhengyu, Xu Xiaoli, Guo Xiaoke, Zhang Xiaojin, Sun Haopeng*, You Qidong, Recent Advances in the Discovery of HIF-1α-p300/CBP Inhibitors as Anti-Cancer Agents, Mini-Reviews in Medicinal Chemistry 2018; 18 (4) . https://dx.doi.org/10.2174/1389557516666160630124938
DOI https://dx.doi.org/10.2174/1389557516666160630124938 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Mitochondria as a Therapeutic Target in Metabolic Disorders
Mitochondria are the primary site of adenosine triphosphate (ATP) production in mammalian cells. Moreover, these organelles are an important source of reactive oxygen and nitrogen species in virtually any nucleated cell type. The modulation of a myriad of cellular signaling pathways depends on the mitochondrial physiology. Mitochondrial dysfunction is observed ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Discovery and Optimization of 1-(4-chloro-3-(trifluoromethyl)- phenyl)-3-(2-(amino)pyridin-3-yl)ureas as Novel KDR Kinase Inhibitors
Medicinal Chemistry Protein Folding and Misfolding, Endoplasmic Reticulum Stress in Neurodegenerative Diseases: in Trace of Novel Drug Targets
Current Protein & Peptide Science Blockers of Voltage-Gated Sodium Channels for the Treatment of Central Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Antioxidant Properties and Polyphenol Screening of the Leaves of Native Hungarian Oak (<i>Quercus</i>) Species
Current Bioactive Compounds Alphaviruses and their Derived Vectors as Anti-Tumor Agents
Current Cancer Drug Targets Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
Current Pharmaceutical Design Recent Highlights on Molecular Hybrids Potentially Useful in Central Nervous System Disorders
Mini-Reviews in Medicinal Chemistry The Potential Role of Pro-Inflammatory and Anti-Inflammatory Cytokines in Epilepsy Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets O-(2-[18F]-Fluoroethyl)-L-Tyrosine (FET) in Neurooncology: A Review of Experimental Results
Current Radiopharmaceuticals Neuroactive Flavonoids Interacting with GABAA Receptor Complex
Current Drug Targets - CNS & Neurological Disorders Novel Colchicine Derivatives and their Anti-cancer Activity
Current Topics in Medicinal Chemistry Origins, Controversies and Recent Developments of the MCI Construct
Current Alzheimer Research Value of Real Time Three Dimensional Transesophageal Echocardiography in General Cardiology Practice
Recent Patents on Medical Imaging Prediction of Plasma Concentration-time Profiles of Drugs in Humans from Animals Following Oral Administration: An Allometric Approach
Current Drug Metabolism Vascular Arginase and Hypertension
Current Hypertension Reviews STAT-3 Inhibitors: State of the Art and New Horizons for Cancer Treatment
Current Medicinal Chemistry Angiotensin Peptides as AT2 Receptor Agonists
Current Protein & Peptide Science Beyond Bile Acids: Targeting Farnesoid X Receptor (FXR) with Natural and Synthetic Ligands
Current Topics in Medicinal Chemistry Antioxidative Effects of Rhodiola Genus: Phytochemistry and Pharmacological Mechanisms against the Diseases
Current Topics in Medicinal Chemistry IL-19 as a Potential Therapeutic in Autoimmune and Inflammatory Diseases
Current Pharmaceutical Design